Overview

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Status:
Completed

Trial end date:
2020-07-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Collaborator:

Ovid Therapeutics Inc.